
The PSMA PET radiopharmaceutical 64Cu-SAR-bisPSMA, which previously garnered two FDA fast track designations, more than doubled the detection of PCa lesions in comparison to 68Ga-PSMA-11 in the phase II Co-PSMA trial.
Catch up on the most-well viewed prostate imaging content in October 2024.
Touching on a variety of topics in prostate cancer imaging, ranging from new research comparing PSMA PET/CT and PSA response after mCRPC treatment to AI advances for PCa detection on mpMRI, here are the top five most well-viewed prostate imaging content from Diagnostic Imaging for October 2024.






